Pharsight

Emd Serono Inc patents expiration

1. Mavenclad patents expiration

MAVENCLAD's oppositions filed in EPO
MAVENCLAD Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785415 EMD SERONO INC Oral formulations of cladribine
Apr, 2024

(6 months from now)

US7888328 EMD SERONO INC Oral formulations of cladribine
Apr, 2024

(6 months from now)

US8377903 EMD SERONO INC Cladribine regimen for treating multiple sclerosis
May, 2026

(2 years from now)

US7713947 EMD SERONO INC Cladribine regimen for treating multiple sclerosis
Oct, 2026

(3 years from now)

US10849919 EMD SERONO INC Cladribine regimen for treating progressive forms of multiple sclerosis
Nov, 2038

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 29, 2022

Drugs and Companies using CLADRIBINE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: Treatment of ms with an admixture of (a) an amorphous inclusion complex of cladribine (2cda) and cyclodextrin and (b) amorphous free 2cda and cyclodextrin as a non-inclusion complex, formulated as a s...

Dosage: TABLET;ORAL

How can I launch a generic of MAVENCLAD before it's drug patent expiration?
More Information on Dosage

MAVENCLAD family patents

Family Patents

2. Tepmetko patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8921357 EMD SERONO INC Pyridazinone derivatives
May, 2028

(4 years from now)

US8329692 EMD SERONO INC Pyrimidinyl pyridazinone derivatives
Oct, 2029

(6 years from now)

US8580781 EMD SERONO INC Pyridazinone derivatives
Mar, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9284300 EMD SERONO INC Pyridazinone derivatives
Apr, 2028

(4 years from now)

US9403799 EMD SERONO INC Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase
Jul, 2028

(4 years from now)

US9062029 EMD SERONO INC Pyrimidinyl pyridazinone derivatives
Jul, 2028

(4 years from now)

US8658643 EMD SERONO INC Pyrimidinyl pyridazinone derivatives
Jul, 2028

(4 years from now)

US8927540 EMD SERONO INC Pyridazinone derivatives
Jul, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 3, 2026
Orphan Drug Exclusivity (ODE) Feb 3, 2028

Drugs and Companies using TEPOTINIB HYDROCHLORIDE ingredient

NCE-1 date: 2025-02-03

Market Authorisation Date: 03 February, 2021

Treatment: Treating a solid tumor, including lung cancer, with a met alteration(s), or stabilizing or improving symptoms associated with having a solid tumor, including lung cancer, with a met alteration(s), by ...

Dosage: TABLET;ORAL

More Information on Dosage

TEPMETKO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic